1837-55-4

Basic information

• Product Name: 3,5-Dichloropyridazine
• Synonyms: 3,5-Dichloropyridazine;SA029519;Pyridazine,3,5-dichloro-
• CAS NO: 1837-55-4
• Molecular Formula: C₄H₂Cl₂N₂
• Molecular Weight: 148.98
• Mol File: 1837-55-4.mol
• Article Data: 4

Chemical Properties

• Melting Point: 60.0 to 64.0 °C
• Boiling Point: 280.8 °C at 760 mmHg
• Flash Point: 150.5 °C
• Appearance: /
• Density: 1.493 g/cm³
• Vapor Pressure: 0.00629mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: DMSO (Sparingly), Methanol (Slightly)
• PKA: -0.25±0.10(Predicted)
• CAS DataBase Reference: 3,5-Dichloropyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Dichloropyridazine(1837-55-4)
• EPA Substance Registry System: 3,5-Dichloropyridazine(1837-55-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 1837-55-4(Hazardous Substances Data)

Usage

Description

3,5-Dichloropyridazine is a chemical compound with the molecular formula C4H2Cl2N2. It is characterized by the presence of two chlorine atoms attached to a pyridazine ring, which is a six-membered aromatic heterocyclic compound containing two nitrogen atoms. 3,5-Dichloropyridazine has potential applications in the pharmaceutical industry due to its unique chemical properties and interactions with biological systems.

Uses

Used in Pharmaceutical Industry:
3,5-Dichloropyridazine is used as a novel histamine H4 antagonist for the treatment of asthma and allergy. Its ability to block the histamine H4 receptor helps in reducing inflammation and other allergic symptoms, providing relief to patients suffering from these conditions.
Additionally, 3,5-Dichloropyridazine has potential antinociceptive and anti-inflammatory effects, which can be beneficial in managing pain and inflammation associated with various conditions. Further research and development are needed to fully understand and harness the therapeutic potential of this compound in the pharmaceutical industry.

InChI:InChI=1/C4H2Cl2N2/c5-3-1-4(6)8-7-2-3/h1-2H

Upstream product

• 1081808-80-1 (Z)-2,4,4,4-tetrachlorobut-2-enal 
• 19429-51-7 2,4,4,4-tetrachloro-but-2-enal 

Downstream Products

• 2096-20-0 3,5-dimethoxypyridazine 
• 1366234-53-8 C₁₆H₁₁Cl₂N₃O 
• 1314978-36-3 5-chloropyridazin-3-amine 
• 697739-36-9 5-chloro-3-(4-fluorophenyl)pyridazine 
• 29049-45-4 3-chloro-5-aminopyridazine 
• 86663-08-3 3-chloro-5-phenyl-pyridazine 

Relevant articles and documents

Energetic Functionalization of the Pyridazine Scaffold: Synthesis and Characterization of 3,5-Diamino-4,6-dinitropyridazine-1-Oxide

The synthesis of 3,5-diamino-4,6-dinitropyridazine-1-oxide (8) is reported. It is prepared in a six-step synthetic procedure starting from acyclic compounds, and shows good properties (detonation velocity DC–J = 8486 m s–1, detonation pressure pC–J = 302 kbar), and sensitivity toward mechanical stimuli. Compound 8 and its precursor (7, 3,5-dimethoxy-4,6-dinitropyridazine-1-oxide) were characterized by means of multinuclear (1H, 13C, 14N, 15N) NMR spectroscopy, mass spectrometry, vibrational spectroscopy (IR and Raman), elemental analysis and differential thermal analysis (DTA) measurements. Compounds 4, 5, 6, 7, 8 and 9 were also characterized by low-temperature single-crystal X-ray diffraction. The heats of formation for 7 and 8 were calculated using the atomization method based on CBS-4M enthalpies. Using the experimentally determined (X-ray) densities and the calculated standard molar enthalpies of formation, several detonation parameters such as the detonation pressure, energy and velocity were predicted by using the EXPLO5 code (V6.03). The sensitivities of 3,5-dimethoxy-4,6-dinitropyridazine-1-oxide (7) and 3,5-diamino-4,6-dinitropyridazine-1-oxide (8) toward impact, friction and electrical discharge were tested according to BAM standards. In addition, the shock reactivity of 8 was measured by applying the small-scale shock reactivity test, showing similar values to HNS, PYX and TKX-55.

GPR52 MODULATOR COMPOUNDS

The disclosures herein relate to novel compounds of Formula (1): (1) and salts thereof, wherein R1, Q, X, Y and Z are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR52 receptors.